Depression in patients with schizophrenia: Prevalence, and diagnostic and treatment considerations

CNS Drugs

Volumn 14, Issue 4, 2000, Pages 289-299

  Hausmann, A ^a   Fleischhacker, W W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOZAPINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NORFLUOXETINE; OLANZAPINE; PAROXETINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIPRASIDONE; ZOTEPINE;

COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHIZOPHRENIA;

EID: 0033790226     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014040-00004     Document Type: Review

References (114)

1. Dementia praecox and paraphrenia
2. Uber die stellungnahme zur abgelaufenen akuten psychose
3. Clinical Psychopathology
4. Semiology and nosology
5. Zur bedeutung des postremissiven erschopfungssyndroms fur die rehabilitation schizophrener
6. The schizophrenic patient and depressive symptomatology
7. Studies of depressive symptoms in schizophrenia. The prevalence of depression and its possible causes
8. Depressions in schizophrenia: Some observations on prevalence, etiology, and treatment
9. Revealed depression and drug treatment for schizophrenia
10. Depressive states occurring during the neuroleptic treatment of schizophrenia
11. Postpsychotic depression in schizophrenia
12. Neuroleptics and operant behavior: The anhedonia hypothesis
13. Dopamine pathways
14. Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved?
15. Depressive syndrome im verlauf neuroleptischer therapie
16. Severe depressive mood changes following slow release intramuscular fluphenazine injection
17. The problem of postpsychotic schizophrenic depressions and their pharmacological induction
18. Drug induced mood disorder
19. Depressive syndrome im verlauf schizophrener psychosen
20. The causality of depression in schizophrenia
21. Dysphoric and depressive symptoms in chronic schizophrenia
22. The nature and prevalence of depression in chronic schizophrenic in-patients
23. Depression and schizophrenia
24. Akinetic depression in schizophrenia
25. Dementai praecox oder die Gruppe der Schizophrenen
26. Prospective prediction of schizophrenic remission
27. Postpsychotic episodes and postpsychotic depression in young adults
28. Manic-depressive illness and good-prognosis schizophrenia
29. Development and prediction of postpsychotic depression in neuroleptic treated schizophrenics
30. The significance of depression in the prediction of relapse in chronic schizophrenia
31. Comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia
32. When a schizoaffective diagnosis has meaning
33. Depression and social adjustment among chronic schizophrenic outpatients
34. Suicide in chronic schizophrenia
35. Depression, hopelessness and suicide in chronic schizophrenia
36. Prodromal symptoms and prevention of relapse in schizophrenia
37. Suicide among schizophrenics: A review
38. Suicidal behavior in patients with schizophrenia and other psychotic disorders
39. The dysphoric syndrome in schizophrenia and its implications for relapse
40. Depressive syndrome im verlaufvon schizophrenien
41. Depression during the longitudinal course of schizophrenia
42. Frequency and differential diagnosis of depressive syndromes in schizophrenia
43. The composition of the negative syndrome of chronic schizophrenia
44. The subjective experience of deficits in schizophrenia
45. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia
46. A depression rating scale for schizophrenics
47. Apsychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale
48. Specificity of the Calgary Scale for schizophrenics
49. Reliability and validity of a depression rating scale for schizophrenics
50. Depression in schizophrenia: A comparison of three measures
51. Die gezielte symptomprovokation mit monoamino-oxydasehemmenden substanzen in diagnostik und therapie schizophrener psychosen
52. Psychiatric reaction pattern to imipramine
53. Experimentelle untersuchung zur differentialindikation von neuroleptika und thymoleptika
54. Imipramine-induced behavioral disorganisation in schizophrenic patients
55. Depression in schizophrenia
56. Treatment of secondary depression in schizophrenia: A doubleblind, placebo-controlled trial of amitriptyline added to perphenazine
57. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial
58. Antidepressant drugs in anergic schizophrenia: A double-blind cross-over study with maprotiline and placebo
59. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized acutely ill psychiatric patients
60. Comparative effects of fluphenazine, fluphenazine-chlodiazepoxide and fluphenazine-imipramine
61. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia
62. Combinations of psychotherapeutic drugs in the treatment of the acutely disturbed psychiatric patient
63. Concept identification and psychophysiological parameters in depressed schizophrenics as functions of imipramine and nialamide
64. Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients
65. Combined perphenazine-amitriptyline as adjuvant therapy in psychiatric aftercare
66. Trifluoperazine combined with amitriptyline in paranoid psychosis
67. Imipramine as an adjunct to phenothiazine therapy
68. Perphenazine combined with amitriptyline in newly admitted schizophrenics
69. Combined drug treatment
70. Evaluation of combined antidepressant and tranquilizing drug (amitriptyline-perphenazine) in the treatment of hospitalized chronic schizophrenic patients
71. The phrenotropic action of perphenazine-amitriptyline
72. Combined amitriptyline and perphenazine in the treatment of severe emotional disorders
73. Combined antidepressant-tranquilizer therapy of mixed psychiatric syndromes
74. Desimipramine in the treatment of long standing psychotic disorders
75. Depression in acute schizophrenic psychosis
76. Amitriptyline-perphenazine in the treatment of schizophrenia
77. Depression and the acute schizophrenic process
78. Some examples of the combined use of psychotropic agents
79. Amitriptyline: Repraisal after six years' experience
80. Amitriptyline, perphenazine and psychotherapy: Combined therapy in 800 patients over four years
81. A long term follow up of fluphenazine enanthrate treatment
82. Pharmacotherapy of impaired affect in recovering schizophrenic patients
83. Antidepressant usage in schizophrenia
84. Treatment of schizoaffective disorder and schizophrenia with mood symptoms
85. Lithium combined with haloperidol in schizophrenic patients
86. Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebocontrolled study
87. Clinically significant interactions of psychotic agents with antipsychotic drugs
88. Interaction of chlorpromazine with tricyclic antidepressants in schizophrenic patients
89. Interaction of chlorpromazine and nortriptyline in patients with schizophrenia
90. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man
91. Neuroleptic effect on desipramine steadystate plasma concentrations
92. Plasma imipramine concentrations in patients receiving concomitant fluphenacine decanoate
93. Elevated levels of clozapine in serum after addition of fluvoxamine
94. Clozapine and metabolites: Serum concentrations and clinical findings during treatment of chronically psychotic patients
95. Serotonin reuptake inhibitors alter metabolism of clozapine
96. EEG alterations in patients treated with clozapine in relation to plasma levels
97. Sexual disturbances during clozapine and haloperidol treatment
98. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects
99. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, netazodone and mirtazapine
100. Psychopharmacology of antipsychotics
101. Neuropharmacology of zotepine, an antimanic drug: A potent blocker of D2 and 5-HT2 receptors of human brain
102. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
103. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: An in vivo microdialysis study in freely moving rats
104. Sustained 5-HT2 receptor occupancy of ziprasidone using the PET ligand setoperone in healthy volunteers [poster]
105. Ziprasidone (CP-88.059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
106. Delusional depression: Treatment with zotepine or haloperidol and antidepressants
107. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
108. Negative symptoms: A path analytic approach to a double-blind placebo and haloperidol controlled clinical trial with olanzapine
109. Effects of Risperidone on affective symptoms in patients with schizophrenia
110. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders
111. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia